364 related articles for article (PubMed ID: 15581592)
1. Progress in cytochrome P450 active site modeling.
Kemp CA; Maréchal JD; Sutcliffe MJ
Arch Biochem Biophys; 2005 Jan; 433(2):361-8. PubMed ID: 15581592
[TBL] [Abstract][Full Text] [Related]
2. Insights into drug metabolism from modelling studies of cytochrome P450-drug interactions.
Maréchal JD; Sutcliffe MJ
Curr Top Med Chem; 2006; 6(15):1619-26. PubMed ID: 16918473
[TBL] [Abstract][Full Text] [Related]
3. Insights into drug metabolism by cytochromes P450 from modelling studies of CYP2D6-drug interactions.
Maréchal JD; Kemp CA; Roberts GC; Paine MJ; Wolf CR; Sutcliffe MJ
Br J Pharmacol; 2008 Mar; 153 Suppl 1(Suppl 1):S82-9. PubMed ID: 18026129
[TBL] [Abstract][Full Text] [Related]
4. Homology modelling of human CYP2 family enzymes based on the CYP2C5 crystal structure.
Lewis DF
Xenobiotica; 2002 Apr; 32(4):305-23. PubMed ID: 12028664
[TBL] [Abstract][Full Text] [Related]
5. Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes.
Lewis DF
Arch Biochem Biophys; 2003 Jan; 409(1):32-44. PubMed ID: 12464242
[TBL] [Abstract][Full Text] [Related]
6. Structural analysis of CYP2C9 and CYP2C5 and an evaluation of commonly used molecular modeling techniques.
Afzelius L; Raubacher F; Karlén A; Jørgensen FS; Andersson TB; Masimirembwa CM; Zamora I
Drug Metab Dispos; 2004 Nov; 32(11):1218-29. PubMed ID: 15483192
[TBL] [Abstract][Full Text] [Related]
7. Flexibility of human cytochrome P450 enzymes: molecular dynamics and spectroscopy reveal important function-related variations.
Hendrychová T; Anzenbacherová E; Hudeček J; Skopalík J; Lange R; Hildebrandt P; Otyepka M; Anzenbacher P
Biochim Biophys Acta; 2011 Jan; 1814(1):58-68. PubMed ID: 20656072
[TBL] [Abstract][Full Text] [Related]
8. Structure conservation in cytochromes P450.
Mestres J
Proteins; 2005 Feb; 58(3):596-609. PubMed ID: 15617063
[TBL] [Abstract][Full Text] [Related]
9. A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102, and P450 108.
de Groot MJ; Vermeulen NP; Kramer JD; van Acker FA; Donné-Op den Kelder GM
Chem Res Toxicol; 1996; 9(7):1079-91. PubMed ID: 8902262
[TBL] [Abstract][Full Text] [Related]
10. Homology modelling of human cytochromes P450 involved in xenobiotic metabolism and rationalization of substrate selectivity.
Lewis DF
Exp Toxicol Pathol; 1999 Jul; 51(4-5):369-74. PubMed ID: 10445400
[TBL] [Abstract][Full Text] [Related]
11. Structural diversity of human xenobiotic-metabolizing cytochrome P450 monooxygenases.
Johnson EF; Stout CD
Biochem Biophys Res Commun; 2005 Dec; 338(1):331-6. PubMed ID: 16157296
[TBL] [Abstract][Full Text] [Related]
12. Sulfaphenazole derivatives as tools for comparing cytochrome P450 2C5 and human cytochromes P450 2Cs: identification of a new high affinity substrate common to those enzymes.
Marques-Soares C; Dijols S; Macherey AC; Wester MR; Johnson EF; Dansette PM; Mansuy D
Biochemistry; 2003 Jun; 42(21):6363-9. PubMed ID: 12767217
[TBL] [Abstract][Full Text] [Related]
13. Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities.
Venhorst J; ter Laak AM; Commandeur JN; Funae Y; Hiroi T; Vermeulen NP
J Med Chem; 2003 Jan; 46(1):74-86. PubMed ID: 12502361
[TBL] [Abstract][Full Text] [Related]
14. Investigating human P450s involved in drug metabolism via homology with high-resolution P450 crystal structures of the CYP2C subfamily.
Lewis DF; Ito Y; Goldfarb PS
Curr Drug Metab; 2006 Aug; 7(6):589-98. PubMed ID: 16918314
[TBL] [Abstract][Full Text] [Related]
15. Investigation of enzyme selectivity in the human CYP2C subfamily: homology modelling of CYP2C8, CYP2C9 and CYP2C19 from the CYP2C5 crystallographic template.
Lewis DF; Dickins M; Lake BG; Goldfarb PS
Drug Metabol Drug Interact; 2003; 19(4):257-85. PubMed ID: 14768974
[TBL] [Abstract][Full Text] [Related]
16. Substrates of human cytochromes P450 from families CYP1 and CYP2: analysis of enzyme selectivity and metabolism.
Lewis DF; Lake BG; Dickins M
Drug Metabol Drug Interact; 2004; 20(3):111-42. PubMed ID: 15508429
[TBL] [Abstract][Full Text] [Related]
17. Theoretical investigation of substrate specificity for cytochromes P450 IA2, P450 IID6 and P450 IIIA4.
De Rienzo F; Fanelli F; Menziani MC; De Benedetti PG
J Comput Aided Mol Des; 2000 Jan; 14(1):93-116. PubMed ID: 10702928
[TBL] [Abstract][Full Text] [Related]
18. Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine.
Ring BJ; Eckstein JA; Gillespie JS; Binkley SN; VandenBranden M; Wrighton SA
J Pharmacol Exp Ther; 2001 Jun; 297(3):1044-50. PubMed ID: 11356927
[TBL] [Abstract][Full Text] [Related]
19. Theoretical study of the ligand-CYP2B4 complexes: effect of structure on binding free energies and heme spin state.
Harris DL; Park JY; Gruenke L; Waskell L
Proteins; 2004 Jun; 55(4):895-914. PubMed ID: 15146488
[TBL] [Abstract][Full Text] [Related]
20. Construction of a 3D model of cytochrome P450 2B4.
Chang YT; Stiffelman OB; Vakser IA; Loew GH; Bridges A; Waskell L
Protein Eng; 1997 Feb; 10(2):119-29. PubMed ID: 9089811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
